Regeneron expects EYLEA HD demand growth in the low to mid-teens in Q3–Q4 2026 amid prefilled syringe push

Q2 revenue increased by 17%, and non-GAAP EPS rose by 11%, demonstrating solid fundamentals. All three key products, Dupixent, EYLEA HD, and Libtayo, recorded the highest quarterly sales in history, confirming balanced growth in the portfolio. With the transition to pre-filled syringes for EYLEA HD, guidance indicates low to mid-10% demand growth for Q3-Q4, ensuring revenue visibility for the second half of the year. The need to confirm improvements in margin structure will be assessed in the next quarter.

Current price is $727.13. Support level is $700 (recent correction low), and resistance level is $750 (previous high). With an RSI of 62.2, it is entering overbought territory, but due to MA misalignment, volatility within a range is expected until the trend is confirmed. Recommend partial entry at $700-710, and a trend-following strategy if it breaks above $750.

On the day of the earnings announcement, the stock price reacted with a +4.02%, reflecting a positive market assessment. The acceleration of the EYLEA HD prefilled syringe transition, the continued expansion of Dupixent indications, and the momentum of Libtayo combination therapy serve as long-term growth drivers. However, the lack of MA alignment necessitates verification of short-term momentum sustainability. Future prescription data and market share indicators are expected to serve as additional catalysts.